1. Home
  2. CET vs NTLA Comparison

CET vs NTLA Comparison

Compare CET & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

HOLD

Current Price

$52.21

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$15.48

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
NTLA
Founded
1929
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CET
NTLA
Price
$52.21
$15.48
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$20.02
AVG Volume (30 Days)
34.4K
6.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
16.92
52 Week Low
$47.13
$7.95
52 Week High
$54.65
$28.24

Technical Indicators

Market Signals
Indicator
CET
NTLA
Relative Strength Index (RSI) 44.34 59.83
Support Level $50.69 $11.73
Resistance Level $52.20 $15.52
Average True Range (ATR) 1.25 1.35
MACD -0.11 0.27
Stochastic Oscillator 36.47 74.29

Price Performance

Historical Comparison
CET
NTLA

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: